EMA Authorised: Firazyr (icatibant) — Takeda Pharmaceuticals International AG

View source ↗

Summary

Authorised status for Firazyr (icatibant) by EMA for hereditary angioedema; MAH Takeda Pharmaceuticals International AG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Firazyr (icatibant)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: Takeda Pharmaceuticals International AG. Decision date: 01/04/2026